Cited by 294Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsBRCA gene mutations in cancer

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Open access

Flaherty, Keith T., Gray, Robert J., Chen, Alice P., Li, Shuli, McShane, Lisa M., Patton, David, Hamilton, Stanley R., Williams, P. Mickey, Iafrate, A. John, Sklar, Jeffrey, Mitchell, Edith P., Harris, Lyndsay N., Takebe, Naoko, Sims, David J., Coffey, Brent, Fu, Tony, Routbort, Mark, Zwiebel, James A., Rubinstein, Larry V., Little, Richard F., Arteaga, Carlos L., Comis, Robert, Abrams, Jeffrey S., O’Dwyer, Peter J., Conley, Barbara A., for the NCI-MATCH team·2020·Journal of Clinical Oncology

DOI 10.1200/jco.19.03010PMC PMC7676882

Open this paper in CoChat — free account

Abstract

PURPOSE: Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in a master screening protocol. Patients with a tumor molecular alteration addressed by a targeted treatment lacking established efficacy in that tumor type were assigned to 1 of 30 treatments in parallel, single-arm, phase II subprotocols. PATIENTS AND METHODS: Tumor biopsy specimens from 5,954 patients with refractory malignancies at 1,117 accrual sites were analyzed centrally with NGS and selected immunohistochemistry in a master screening protocol. The treatment-assignment rate to treatment arms was assessed. Molecular alterations in seven tumors profiled in both NCI-MATCH trial and The Cancer Genome Atlas (TCGA) of primary tumors were compared. RESULTS: Molecular profiling was successful in 93.0% of specimens. An actionable alteration was found in 37.6%. After applying clinical and molecular exclusion criteria, 17.8% were assigned (26.4% could have been assigned if all subprotocols were available simultaneously). Eleven subprotocols reached their accrual goal as of this report. Actionability rates differed among histologies (eg, > 35% for urothelial cancers and < 6% for pancreatic and small-cell lung cancer). Multiple actionable or resistance-conferring tumor mutations were seen in 11.9% and 71.3% of specimens, respectively. Known resistance mutations to targeted therapies were numerically more frequent in NCI-MATCH than TCGA tumors, but not markedly so. CONCLUSION: We demonstrated feasibility of screening large numbers of patients at numerous accruing sites in a complex trial to test investigational therapies for moderately frequent molecular targets. Co-occurring resistance mutations were common and endorse investigation of combination targeted-therapy regimens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.19.03010

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Maftools: efficient and comprehensive analysis of somatic variants in cancerPreprint
Mayakonda, A., Lin, D., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 5,005
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
circlize implements and enhances circular visualization in R
Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu393 · Cited by 4,290
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“7) Median age, years (range) 62 (18-94) 62 (18-94) 62 (18-92) 61 (19-85)”
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 101–200 of 293

Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review
Motohashi, S., Katsuta, E., & Ban, D. (2025) · Bioengineering · doi:10.3390/bioengineering12121315 · Cited by 14
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
Nakamura, Y., Yamashita, R., Okamoto, W., Komatsu, Y., Yuki, S., Ueno, M., Kato, K., Taniguchi, H., Kagawa, Y., Denda, T., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00653 · Cited by 13
Clinical Network Systems Biology: Traversing the Cancer Multiverse
Mambetsariev, I., Fricke, J., Gruber, S. B., Tan, T., Babikian, R., Kim, P., Vishnubhotla, P., Chen, J., Kulkarni, P., & Salgia, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134535 · Cited by 13
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Bhatia, K. S., Sandhu, V., Wong, M. H., Iyer, P., & Bhatt, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1275251 · Cited by 13
Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
Imai, M., Nakamura, Y., Sunami, K., Kage, H., Komine, K., Koyama, T., Amano, T., Ennishi, D., Kanai, M., Kenmotsu, H., et al. (2022) · Cancer Science · doi:10.1111/cas.15504 · Cited by 12
An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry
Tourneau, C. L., Perret, C., Hackshaw, A. K., Blay, J., Nabholz, C. E., Geißler, J., Do, T., von Meyenn, M., & Dienstmann, R. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00019 · Cited by 13
Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now?
Oberoi, S., Choy, E., Chen, Y., Scharschmidt, T. J., & Weiss, A. R. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01059-2 · Cited by 13
Can Systems Biology Advance Clinical Precision Oncology?
Rocca, A., & Kholodenko, B. Ν. (2021) · Cancers · doi:10.3390/cancers13246312 · Cited by 13
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 11
Assessment of Two Commercial Comprehensive Gene Panels for Personalized Cancer Treatment
Ottestad, A. L., Huang, M., Emdal, E. F., Mjelle, R., Skarpeteig, V., & Dai, H. Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010042 · Cited by 12
Next-generation sequencing in oncology: challenges in economic evaluations
Ehman, M., Punian, J., Weymann, D., & Regier, D. A. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2388814 · Cited by 12
Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials
Hoosemans, L., Vooijs, M., & Hoeben, A. (2024) · Cancers · doi:10.3390/cancers16173021 · Cited by 13
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients
Mizuno, T., Yoshida, T., Sunami, K., Koyama, T., Okita, N. T., Kubo, T., Sudo, K., Shimoi, T., Ueno, H., Saito, E., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab159 · Cited by 11
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
Omura, T., Takahashi, M., Ohno, M., Miyakita, Y., Yanagisawa, S., Tamura, Y., Kikuchi, M., Kawauchi, D., Nakano, T., Hosoya, T., et al. (2022) · Cancers · doi:10.3390/cancers14102454 · Cited by 11
Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic Development
Yap, T. A., Stadler, Z. K., Stout, L. A., & Schneider, B. P. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390738 · Cited by 11
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
Heilig, C. E., Horak, P., Kreutzfeldt, S., Teleanu, V., Möck, A., Renner, M., Bhatti, I. A., Hutter, B., Hüllein, J., Fröhlich, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100310 · Cited by 11
Global Implementation of Precision Oncology
Yam, C., Ma, B. B. Y., & Yap, T. A. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00001 · Cited by 11
Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors
Giannoudis, A., Sokol, E. S., Bhogal, T., Ramkissoon, S. H., Razis, E. D., Bartsch, R., Shaw, J., McGregor, K., Clark, A., Huang, R. S. P., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00761-0 · Cited by 11
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
Riner, A. N., Velazquez-Villarreal, E. I., Rajpara, S., Qian, J., Jin, Y., Loza, D., Akki, A. S., Herremans, K. M., Raj, R., Williams, T. M., et al. (2025) · Pancreas · doi:10.1097/mpa.0000000000002408 · Cited by 8
The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer
Liu, C.-L., Yuan, R., & Mao, T. (2021) · Biomolecules · doi:10.3390/biom11070998 · Cited by 10
Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer
Markt, S. C., Booker, B. D., Bensken, W. P., Schiltz, N. K., Schumacher, F. R., Rose, J., Cooper, G. S., Selfridge, J. E., & Koroukian, S. M. (2022) · Cancer Medicine · doi:10.1002/cam4.4995 · Cited by 10
Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy
Zhang, Q., Zhang, J., Liu, Z., Wang, J., Wang, F., Wang, T., Shi, F., Su, J., & Zhao, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s429180 · Cited by 10
Assessing patient-level knowledge of precision medicine in a community health center setting
Stallings, S., Richmond, J., Canedo, J., Beard, K. R., Bonnet, K. R., Schlundt, D. G., Wilkins, C. H., & Aldrich, M. C. (2023) · Journal of Community Genetics · doi:10.1007/s12687-023-00632-4 · Cited by 11
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
Jiao, X., Qin, B., Wang, Z., Liu, K., Wu, Y., Ling, Y., Qin, W., Wang, M., Yuan, L., Barreto, S. G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.860711 · Cited by 9
Identifying cancer driver genes in individual tumours
Gillman, R., Field, M. A., Schmitz, U., Karamatic, R., & Hebbard, L. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.019 · Cited by 9
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements
Kimmerling, R. J., Stevens, M. M., Olçum, S., Minnah, A., Vacha, M., LaBella, R., Ferri, M., Wasserman, S. C., Fujii, J., Shaheen, Z., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04270-3 · Cited by 8
Targeting rare tumors: new focus for clinical research in China
Wang, S., Jiang, Y., Miao, H., Fang, Y., Jiang, N., Yu, Y., Ma, P., Tang, Q., Cui, D., Fang, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216415 · Cited by 9
Comprehensive Genome profile testing in head and neck cancer
Kuroki, M., Iinuma, R., Okuda, H., Terazawa, K., Shibata, H., Mori, K., Ohashi, T., Makiyama, A., Futamura, M., Miyazaki, T., et al. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2023.04.006 · Cited by 9
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center
Kraus, F. B. T., Sultova, E., Heinrich, K., Jung, A., Westphalen, C. B., Tauber, C. V. I., Kumbrink, J., Rudelius, M., Klauschen, F., Greif, P. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042345 · Cited by 9
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22–09
Kim, S. Y., Kim, J. H., Kim, T.-Y., Park, S. R., Yoon, S., Lee, S. H., Lee, S.-H., Kim, T. M., Han, S.-W., Kim, H. R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12338-y · Cited by 9
Establishment and validation of psoriasis evaluation models
Hu, Y., Jiang, L., Lei, L., Luo, L., Guo, H., Zhou, Y., Huang, J., Chen, J., & Zeng, Q. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.08.020 · Cited by 9
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers?
Chan, K., & Tannock, I. F. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00552 · Cited by 9
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
Tourneau, C. L., André, F., Helland, Å., Mileshkin, L., Minnaard, W., Schiel, A. E., Taskén, K., Thomas, D. M., Veronese, M. L., Durán-Pacheco, G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113278 · Cited by 8
An interpretable deep learning framework for genome-informed precision oncology
Ren, S., Cooper, G. F., Chen, L., & Lu, X. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00866-y · Cited by 8
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma
Ledford, A., Rodriguez, A., Lipinski, L., Abad, A. P., Fenstermaker, R. A., Edenfield, J., Kanos, C. C., Redjal, N., Mansouri, A., Zacharia, B. E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68801-0 · Cited by 8
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
Kim, T.-Y., Kim, S. Y., Kim, J. H., Jung, H. A., Choi, Y. J., Hwang, I. G., Cha, Y., Gw, L., Lee, Y.-G., Kim, T. M., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103709 · Cited by 8
TARGET National: A UK-wide Liquid-based Molecular Profiling Programme
Ortega-Franco, A., Darlington, E., Greystoke, A., & Krebs, M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.10.005 · Cited by 9
Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program
Vashistha, V., Katsoulakis, E., Guo, A., Price, M. J., Ahmed, S., & Kelley, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00518 · Cited by 8
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial
Mangat, P. K., Garrett-Mayer, E. S., Perez, J. K., & Schilsky, R. L. (2023) · Clinical Trials · doi:10.1177/17407745231182013 · Cited by 8
Proteogenomics drives therapeutic hypothesis generation for precision oncology
Lei, J. T., & Zhang, B. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01346-5 · Cited by 8
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study
Leyvraz, S., Konietschke, F., Peuker, C. A., Schütte, M., Kessler, T., Ochsenreither, S., Ditzhaus, M., Sprünken, E. D., Dörpholz, G., Lamping, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.004 · Cited by 8
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing
Pruis, M. A., Groenendijk, F. H., Badloe, K. S., van Puffelen, A. J., Robbrecht, D. G. J., Dinjens, W. N. M., Sleijfer, S., Dingemans, A. C., von der Thüsen, J. H., Roepman, P., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01841-3 · Cited by 8
The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan
Yoshida, T., Yatabe, Y., Kato, K., Ishii, G., Hamada, A., Mano, H., Sunami, K., Yamamoto, N., & Kohno, T. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0036 · Cited by 8
Machine Learning Based Classification of Chronic Kidney Disease Using CT Scan Images
Ali, A., Naeem, S., & ZUBAIR, M. (2022) · MOL2NET International Conference on Multidisciplinary Sciences (MOL2NET) · doi:10.3390/mol2net-08-13903 · Cited by 7
Targeting the breast tumor microenvironment by plant-derived products and their nanoformulations
Zhang, H., & Li, Y. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105432 · Cited by 7
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
Antar, R. M., Fawaz, C., Gonzalez, D., Xu, V. E., Drouaud, A., Krastein, J., Pio, F., Murdock, A., Youssef, K., Sobol, S. M., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110511 · Cited by 7
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers
Wolford, J. E., Ferrigni, E. N., Margul, D. J., & Herzog, T. J. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01163-2 · Cited by 8
Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study
Patil, D., Akolkar, D. B., Nagarkar, R. V., Srivastava, N., Datta, V., Patil, S., Apurwa, S., Srinivasan, A., & Datar, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.972322 · Cited by 7
Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment
Teleanu, M., Schneider, A., Ball, C. R., Leber, M. F., Stange, C., Krieghoff‐Henning, E., Beck, K., Heilig, C. E., Kreutzfeldt, S., Küster, B., et al. (2025) · Biomolecules · doi:10.3390/biom15050693 · Cited by 6
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Luke, J. J., Bever, K. M., Hodi, F. S., Taube, J. M., Massey, A., Yao, D., Neely, J., Tam, R., Lee, G., Gupta, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011170 · Cited by 6
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Drenner, K., Basu, G. D., Goodman, L. J., Ozols, A. A., Lobello, J. R., Royce, T. E., Gordon, M. S., Borazanci, E. H., Steinbach, M. A., Trent, J. M., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.28046 · Cited by 6
Biomarkers for therapy selection in metastatic urothelial cancer
Jun, T. W., Anker, J. F., & Galsky, M. D. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.171 · Cited by 8
Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use
Shi, Z., Lopez, J. A., Kalliney, W., Sutton, B. C., Simpson, J., Maggert, K., Liu, S., Wan, J., & Stack, M. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266914 · Cited by 6
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors
Cotler, M. J., Ramadi, K. B., Hou, X., Christodoulopoulos, E., Ahn, S. W., Bashyam, A., Ding, H., Larson, M. C., Oberg, A. L., Whittaker, C. A., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101427 · Cited by 6
Consensus Statements on Precision Oncology in the China Greater Bay Area
Lam, T.-C., Cho, W. C. S., Au, J. S. K., Ma, E. S. K., Lam, S. T., Loong, H. H.-F., Wong, J. W. H., Wong, S. N. M., Lee, V. H.-F., Leung, R. C.-Y., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00649 · Cited by 6
Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care
Ewongwo, A. N., Hui, C., & Moding, E. J. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.12.002 · Cited by 6
The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
Orlov-Slavu, M. C., Popa, A. M., Tulin, A. D., Stoian, A. P., Poiană, C., Paleru, C., Calu, V., & Niţipir, C. (2021) · Cureus · doi:10.7759/cureus.16919 · Cited by 6
Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine
Kordyukova, M., Bulgakov, T. K., Sorokina, M. A., Kudryashova, O. M., Abakumova, T. O., Meshcheryakova, V., Grigoriev, I. V., Senko, I. V., Shevchenko, E. K., & Belousov, V. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052207 · Cited by 6
Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference
Lynch, S. M., Heeran, A. B., Burke, C., Lynam‐Lennon, N., Eustace, A. J., Dean, K. A., Robson, T., Rahman, A., & Marcone, S. (2024) · Cancers · doi:10.3390/cancers16111989 · Cited by 6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi, F., Shrestha, N., Liu, T. F. D., Foord, T. H., Heesen, P., Booth, S. W., Dodwell, D. J., Lord, S., Yeoh, K., & Blagden, S. P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014872.pub2 · Cited by 8
Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine
Rahman, R. M. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000549 · Cited by 5
Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients.
Xiong, A., Ma, N., Wei, G., Li, C., Li, K., & Wang, B. (2021) · PubMed Central · Cited by 5
Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment
Morikawa, A., Li, J., Ulintz, P., Cheng, X., Apfel, A. M., Robinson, D. R., Hopkins, A., Kumar‐Sinha, C., Wu, Y., Serhan, H. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0492 · Cited by 6
Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy
de Nigris, F., Meo, C., & Palinski, W. (2023) · Cells · doi:10.3390/cells12172204 · Cited by 5
Mutational landscape of gastric adenocarcinoma in Latin America: A genetic approach for precision medicine
Cerrato-Izaguirre, D., Chirino, Y. I., García-Cuellar, C. M., Santibáñez-Andrade, M., Prada, D., Hernández-Guerrero, A., Lárraga, O. A., Camacho, J., & Sánchez-Pérez, Y. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.04.002 · Cited by 5
Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer TypesPreprint
Storey, C. M., Cheng, M., Altai, M., Park, J. E., Tran, J., Lueong, S., Thorek, D. L. J., Mao, L., Zedan, W., Yuen, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.22.624939 · Cited by 5
Functional drug screening of tumor organoids on an active-matrix digital microfluidic chip for cancer precision medicine
Sun, R., Feng, Z., Wu, T., Ding, F., Wu, Y., Jin, K., Li, L., Jia, Z., Gao, R., Cong, Y., et al. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01215-2 · Cited by 6
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Gouda, M. A., Jankú, F., Yuan, Y., Drusbosky, L. M., Chen, A. P., Zheng, X., Patel, K. P., Hamilton, S. R., Routbort, M. J., Tricoli, J. V., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3531 · Cited by 5
Self-citation
Molecular advances in early-stage and locally advanced non-small cell lung carcinoma: Shaping the future of precision oncology-systematic review
Hassan, W. A. (2025) · Science Progress · doi:10.1177/00368504251383055 · Cited by 5
Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies
Dawood, S. S., Natarajan, V., & Danchaivijitr, P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374087 · Cited by 4
Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology
Vince, C. S. C., Brassesco, M. S., Mançano, B. M., Gregianin, L. J., Carbone, E. K., Castro, A. D. A. E., Yamachira, V. S., da Silva, R. Z. M., Mariano, C. S., da Mata, J. F., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00713 · Cited by 3
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
McCourt, C. K., Wei, Z., Kalinsky, K. M., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., Williams, P. M., Hamilton, S. R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3431 · Cited by 5
Self-citation
Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
Hamdan, D., Marisa, L., Tlemsani, C., Angeli, E., Soussan, M., Derive, N., Laurent‐Puig, P., & Bousquet, G. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00582 · Cited by 4
Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer—The Possibility or the Necessity?
Wilczyński, J. R., Paradowska, E., & Wilczyński, M. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm14010049 · Cited by 4
Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention
Bylicky, M. A., Shankavaram, U. T., Aryankalayil, M. J., Chopra, S., Naz, S., Sowers, A. L., Choudhuri, R., Calvert, V. S., Petricoin, E. F., Eke, I., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0796 · Cited by 4
Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study
Dreikhausen, L., Klupsch, A., Wiest, I., Xiao, Q., Schulte, N., Betge, J., Boch, T., Brochhausen, C., Gaiser, T., Hofheinz, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12261-2 · Cited by 4
Drug development in the era of precision medicine in oncology—Clues beyond randomization
du Rusquec, P., Filleron, T., & Tourneau, C. L. (2021) · Chinese Clinical Oncology · doi:10.21037/cco-21-29 · Cited by 4
Drug combination prioritization for cancer treatment using single-cell RNA-seq based transfer learningPreprint
Osorio, D., McGrail, D. J., Sahni, N., & Yi, S. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487357 · Cited by 4
A high-throughput 3D culture microfluidic platform for multi-parameter phenotypic and omics profiling of patient-derived organoidsPreprint
Botrugno, O. A., Bianchi, E., Bruno, J. M., Gallo, G. F. M., Felici, C., Sommella, E., Stefano, P. D., Giansanti, V., Rossella, V., Merciai, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.28.630600 · Cited by 4
Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository
Kitadai, R., Okuma, Y., Shibata, T., Kohno, T., & Koyama, T. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115380 · Cited by 3
Understanding the prospective of gene therapy for the treatment of breast cancer
Ritika, R., Rani, S., Malviya, R., Rajput, S., Sridhar, S. B., & Kaushik, D. (2025) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2025.100683 · Cited by 4
Outcomes for Patients Aged 12–18 Months With Metastatic MYCN Non‐Amplified Neuroblastoma and Unfavorable Biologic Features (“Mixed Biology Toddlers”): A Report From the International Neuroblastoma Risk Group (INRG) Project
Taylor, M. R., Anderson, J. R., Park, J. R., Irwin, M. S., Applebaum, M. A., Pinto, N. R., Streby, K. A., Federico, S. M., Rosswog, C., Ohira, M., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31968 · Cited by 3
Precision oncology in rare tumors: Have the orphans been adopted?
Mechahougui, H., Friedlaender, A., Görgülü, K., Tsantoulis, P. K., Illert, A. L., Subbiah, V., Wahida, A., & Kurzrock, R. (2026) · Med · doi:10.1016/j.medj.2025.100958 · Cited by 4
Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies
Weiss, L., Zhang, D., Kunz, W. G., Boeck, S. H., Curigliano, G., Subbiah, V., Lordick, F., Brummer, T., Westphalen, C. B., & Bielo, L. B. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100129 · Cited by 4
Exploring Endophytes as a Treasure House of Bioprospecting Compounds, Emphasizing Their Significance in the Agricultural and Pharmaceutical Fields
Bhakat, A., Das, P., Goswami, M., Sen, S., & Sarkar, K. (2025) · Sustainable landscape planning and natural resources management · doi:10.1007/978-3-031-82178-3_3 · Cited by 3
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization
Lorenzini, D., Salvatori, R., Volpi, C. C., Trupia, D. V., Niger, M., Nichetti, F., Duca, M., Damian, S., Busico, A., Bertolotti, A., et al. (2025) · Tumori Journal · doi:10.1177/03008916251345409 · Cited by 3
Molekulare Tumorboards – Einblicke und Ausblicke
Laßmann, S., & Hummel, M. (2021) · Der Pathologe · doi:10.1007/s00292-021-00955-4 · Cited by 3
Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)
Kong, G., Boehm, E., Prall, O. W. J., Murray, W. K., Tothill, R. W., & Michael, M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01381-w · Cited by 3
Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases
Walpole, I., Zaman, F. Y., Zhao, P., Marshall, V. M., Lin, F. P. Y., Thomas, D. M., Shackleton, M. J., Antolín, A. A., & Ameratunga, M. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1657 · Cited by 3
Biomarker-driven basket trial designs: origins and new methodological developments
Tu, Y., & Renfro, L. A. (2024) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2024.2358806 · Cited by 3
Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort
Kaluziak, S. T., Codd, E. M., Purohit, R., Melli, B., Kalyan, P., Fordham, J. A., Kirkpatrick, G., McShane, L. M., Chang, T.-C., Yang, G., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00493 · Cited by 3
Self-citation
Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
Córdova‐Delgado, M., Pinto, M. P., Regonesi, C., Cereceda, L., Reyes, J. M., Itriago, L., Majlis, A., Rodríguez, P., Fassler, A., Mauricio Mahave, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020195 · Cited by 3
A cross‐sectional study of the FDA approved indications and supporting pivotal trials of small‐molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene
Huang, Y., Xiong, W., Ma, L., & Wu, H. (2022) · International Journal of Cancer · doi:10.1002/ijc.34222 · Cited by 3
Functional proteomic analysis, a missing piece for understanding clonal evolution and cooperation in the tissue microecology
Pierobon, M., & Petricoin, E. F. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2277371 · Cited by 3
The potential of artificial intelligence and machine learning in precision oncology
Alzaabi, A. A., Bouchareb, Y., & Mula‐Hussain, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21598-8.00003-8 · Cited by 2
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Gien, L. T., Song, Z., Poklepovic, A. S., Collisson, E. A., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00514 · Cited by 2
Self-citation
Cancer Dependency Map: Past and Present
Arafeh, R., Shibue, T., Vázquez, F., & Hahn, W. C. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-024239 · Cited by 3
Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer
Dirner, A., Kormos, D., Lakatos, D., Bolyácz, M., Kocsis-Steinbach, M., Kalmár, G. G., Tihanyi, D., Takács, Á., Boldizsár, Á., Kardos, V., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00943-4 · Cited by 2
Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer
DeBortoli, E., McGahan, E., Yanes, T., Berkman, J. L., Aoude, L. G., Smit, A. K., Gokoolparsadh, A., Hermes, A., Newett, L., Bourke, M., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71080 · Cited by 4
Genomics of cervical, vulvar and vaginal cancers and the potential of precision medicine
Barker, H. E., Polidano, J., Jarratt, A., & Scott, C. L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251363499 · Cited by 2

Authors: Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., Mitchell, E. P., Harris, L. N., Takebe, N., Sims, D. J., Coffey, B., Fu, T., Routbort, M., Zwiebel, J. A., Rubinstein, L. V., Little, R. F., Arteaga, C. L., Comis, R., Abrams, J. S., O’Dwyer, P. J., Conley, B. A., & for the NCI-MATCH team
Affiliations: Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
National Institutes of Health (US)
The University of Texas MD Anderson Cancer Center (US)
Frederick National Laboratory for Cancer Research (US)
Harvard University (US)
Yale University (US)
Thomas Jefferson University Hospital (US)
Harold C. Simmons Comprehensive Cancer Center (US)
ECOG-ACRIN Cancer Research Group (US)
Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD
Corresponding author: Flaherty, Keith T.
ORCID: Flaherty, Keith T.
Gray, Robert J.
Chen, Alice P.
Li, Shuli
McShane, Lisa M.
Patton, David
Hamilton, Stanley R.
Williams, P. Mickey
Iafrate, A. John
Sklar, Jeffrey
Mitchell, Edith P.
Harris, Lyndsay N.
Takebe, Naoko
Coffey, Brent
Routbort, Mark
Zwiebel, James A.
Rubinstein, Larry V.
Little, Richard F.
Arteaga, Carlos L.
Abrams, Jeffrey S.
Conley, Barbara A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2020-11-20
Volume: 38
Issue: 33
Pages: 3883-3894
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.19.03010
PMC: PMC7676882
OpenAlex: W3092241364
Cited by: 294
References: 27
Citations by year: 2026: 35 · 2025: 41 · 2024: 51 · 2023: 68 · 2022: 55 · 2021: 41 · 2020: 3
FWCI: 14.31
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Journal of Clinical Oncology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
The Medicine Forum (submittedVersion, cc-by)
Funders: National Cancer Institute (U10CA180820, UG1CA233337, UG1CA233329, UG1CA233180, UG1CA233341, U10CA180794, UG1CA233302, U24CA196172)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: NCI-MATCH trial, actionable molecular alterations, targeted therapy, molecular profiling, next-generation sequencing, resistance mutations, combination targeted therapy, refractory cancer, urothelial carcinoma, pancreatic cancer, small cell lung cancer
MeSH terms: Adolescent, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Female, Humans, Male, Middle Aged, Neoplasms, Disease Progression, Young Adult, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks